Zimmer Biomet Holdings Inc

Latest Results (30.08.2026):

Zimmer Biomet Holdings, Inc. reported results for the quarter ended March 31, 2026 (first quarter 2026). The company posted net sales of $2.087 billion, posted double-digit adjusted EPS growth, generated strong operating and free cash flow, and updated its full-year 2026 guidance, with management calling the quarter a solid start to the year.

Net sales

First quarter 2026 net sales were $2.087 billion, up 9.3% reported, 6.8% on a constant currency basis and 2.9% on an organic constant currency basis (excluding the April 2025 Paragon 28 acquisition).

Earnings

GAAP net earnings were $238.1 million. Diluted GAAP EPS was $1.22 (up 34.1%), while adjusted diluted EPS was $2.09 (up 15.5%). The company also reported adjusted net earnings of $409.4 million.

Cash flow

Zimmer Biomet generated $359.4 million of operating cash flow and $245.9 million of free cash flow in Q1 2026.

Guidance update

Management updated full-year 2026 financial guidance, raising its adjusted EPS guidance and increasing its free cash flow expectations based on first-quarter performance and ongoing go-to-market changes.

Capital returns

The company completed $250 million of share repurchases during the first quarter of fiscal 2026.

Product, clinical and strategic milestones

Notable items included appointment of a Chief Science, Technology and Medical Affairs Officer, enrollment completion in an India study of the mBôs robotic TKA system, FDA 510(k) clearance and first U.S. case for the G7 Acetabular System, commercial launch of ROSA Knee with OptimiZe, and other product launches and recognitions.

Non-GAAP and contingent items

The release uses non-GAAP (adjusted) measures and discloses reconciliations; management noted an initial assessment that no goodwill impairment will be recorded in Q1 2026 but final fair value assessment is pending and could change reported GAAP results.